Pentazocine

Pentazocine
Clinical data
AHFS/Drugs.comMonograph (hydrochloride)
Monograph (lactate)
Pregnancy
category
  • AU: C
Routes of
administration
By mouth, intramuscular, intravenous
Drug classκ-Opioid receptor agonist; μ-Opioid receptor agonist–antagonist; Opioid analgesic; Hallucinogen
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability~20% orally
MetabolismHepatic
Onset of action15 min
Elimination half-life2 to 3 hours
ExcretionRenal
Identifiers
  • (2RS,6RS,11RS)-6,11-dimethyl-3-(3-methylbut-2-en-1-yl)-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-8-ol
    or
    2-dimethylallyl-5,9-dimethyl-2'-hydroxybenzomorphan
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.006.032
Chemical and physical data
FormulaC19H27NO
Molar mass285.431 g·mol−1
3D model (JSmol)
  • Oc1ccc3c(c1)[C@]2([C@H]([C@H](N(CC2)C\C=C(/C)C)C3)C)C
  • InChI=1S/C19H27NO/c1-13(2)7-9-20-10-8-19(4)14(3)18(20)11-15-5-6-16(21)12-17(15)19/h5-7,12,14,18,21H,8-11H2,1-4H3/t14-,18+,19+/m0/s1 checkY
  • Key:VOKSWYLNZZRQPF-GDIGMMSISA-N checkY
  (verify)

Pentazocine, sold under the brand name Talwin among others, is an opioid analgesic medication used to treat moderate to severe pain. Pentazocine activates (agonizes) κ-opioid receptors (KOR) and μ-opioid receptors (MOR). It shares many of the side effects of other opioids like constipation, nausea, itching, drowsiness, and respiratory depression, but, unlike most other opioids, it fairly frequently causes hallucinations, nightmares, and delusions. It is also, unlike most other opioids, subject to a ceiling effect, which is when at a certain dose no more pain relief is obtained by increasing the dose any further.

Chemically it is classed as a benzomorphan and it comes in two enantiomers.

It was patented in 1960 and approved for medical use in 1964. Usually, in its oral formulations, it is combined with naloxone so as to prevent people from crushing the tablets, dissolving them in saline and injecting them for a high (as orally administered naloxone produces no opioid-negating effects as it has no oral bioavailability, whereas intravenous or intramuscular administration does).